Naresh Bumma, MD
Hematology · Columbus, OHNPI 1346504412
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $67,516 of the $109,226 with a category attached, or 61.8%. 11 manufacturers reported payments, led by Amgen at 50.4% of the total. Reporting peaked in 2021 at $33,540 and has fallen 94.9% since, to $1,723 in 2025. Among hematology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $902.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$55K
- Sanofi$31K
- Alnylam Pharmaceuticals Inc.$8K
- Johnson & Johnson$6K
- Regeneron$5K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $2K from 5 others
Across 452 payments — averaging $10,778 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3.7M
- AstraZeneca$551K
- Janssen Research & Development, LLC$308K
- Bristol Myers Squibb$222K
- AbbVie$58K
- E.r. Squibb & Sons, L.L.C.$21K
What the payments were for
- Consulting fees$29,75127%
- Speaking & faculty fees$67,51662%
- Travel & lodging$9,6909%
- Food & beverage$2,2692%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 66 | $55,042 |
| Sanofi | 20 | $31,243 |
| Alnylam Pharmaceuticals Inc. | 11 | $8,020 |
| Johnson & Johnson | 6 | $6,455 |
| Regeneron | 2 | $4,704 |
| Regeneron Healthcare Solutions, Inc. | 5 | $1,400 |
| Bristol Myers Squibb | 5 | $1,043 |
| Janssen Scientific Affairs, LLC | 1 | $840 |
| Karyopharm Therapeutics Inc. | 2 | $324 |
| Adaptive Biotechnologies Corporation | 2 | $139 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$109,226 in reported general payments places this provider in the 90th percentile of 84 hematology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NinlaroIxazomib Citrate | 40 | $536,353 |
| VyndamaxTafamidis | 19 | $463,430 |
| VenclextaVenetoclax | 18 | $87,404 |
| EliquisApixaban | 12 | $11,911 |
| Acyclovir | 89 | $1,373 |
| Ondansetron Hcl | 13 | $374 |
| Fluticasone Propionate | 16 | $123 |
Paid to pharmacies, not to this prescriber.
Other hematology in Columbus
- Uma BorateColumbus$323K
- Sam PenzaColumbus$256K
- Spero CatalandColumbus$245K
- Kami MaddocksColumbus$236K
- Narendranath EpperlaColumbus$199K
- Yvonne EfeberaColumbus$169K
- Kerry RogersColumbus$100K
- Jennifer WoyachColumbus$73K
- Hannah ChoeColumbus$72K
- Alice MimsColumbus$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.